Skip to main content

Celsee, Kindstar Ink Chinese Distribution Deal for Single-Cell Isolation Platform

NEW YORK — Celsee has signed an agreement under which its Genesis single-cell isolation platform and other products will be distributed in China by Kindstar Global, the companies said on Tuesday.

Launched in late 2018, the Genesis platform uses two different slide technologies: Celsingle, which captures and isolates individual cells from both liquid and tissue samples, and Celselect, which enriches and enumerates circulating tumor cells (CTCs) with high capture efficiency and detection rates.

As part of the agreement, Kindstar will purchase an undisclosed number of Genesis platforms for use by scientists at its Kindstar Laboratory System to monitor CTCs in lung, breast, and bladder cancers, as well as for single-cell research. 

Additional terms of the deal were not disclosed.

The companies noted that Kindstar researchers will use InCellDx's BioInk kit for CTC enumeration in therapeutic monitoring on the Genesis system. In August, Kindstar, which has offices in Wuhan, China and in Singapore, signed on to use and distribute in China three of InCellDx's single-cell immuno-oncology and oncology diagnostic products.

"Our team has worked closely with IncellDx to develop workflows that combine our single-cell tools with their flow cytometry classification assays and BioInk assays for CTC enumeration to assess disease progression and response to therapy," Celsee CEO John Stark said in a statement. The company is based in Ann Arbor, Michigan.